Gemin X Pharmaceuticals
Montr├⌐al · Founded 1998
About Gemin X Pharmaceuticals
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.
Company Facts
- Founded: 1998
- Legal name: Gemin X Pharmaceuticals, Inc.
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $71.3M
- Funding stage: M&A
- Last round: Series E (Aug 2010)
- Website: geminx.com
- Phone: +1 (514)281-8989
Canonical: https://fsome.com/organization/gemin-x-pharmaceuticals-8438507 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.